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The literature is sparse in terms of the effect of exercise on the pharmacokinetics of fluoride (F) in 22 
humans. In a 4-treatment repeated measures cross-over study, we investigated F pharmacokinetics 23 
following no exercise (control) and three exercise intensity conditions (light, moderate and vigorous) 24 
in healthy adults. At a pre-experimental session, 8 participants (18-30y) residing in a non-fluoridated-25 
area, underwent a VO2 max test to guide the three exercise intensities for the experimental sessions. 26 
Participants were on a F-free regime one week before and throughout the four experimental weeks. 27 
We measured urinary F excretion (UFE), maximum plasma concentration (Cmax), lag time of Cmax 28 
(Tmax), and Area Under the Curve (AUC) for plasma F concentration against time, following F 29 
ingestion then no, light, moderate and vigorous exercise. Results showed no statistically significant 30 
difference in Tmax among all sessions; whereas Cmax for moderate exercise (226.2ng/ml) was 31 
significantly higher than for no (27.0ng/ml;p<0.001), light (105.6ng/ml;p=0.016) and vigorous 32 
(94.2ng/ml; p=0.008) exercise. Mean AUC over 0 to 90 min following F ingestion was also 33 
significantly higher in moderate exercise than for no (p<0.001), light (p=0.004) and vigorous 34 
(p=0.001) exercise.  Mean UFE over 0-14h was 638.8, 718.7, 574.6 and 450.5µg for no, light, 35 
moderate and vigorous exercise, with no statistically significant differences among different sessions. 36 
In conclusion, this human experimental study suggests that moderate exercise may increase the 37 
fraction of F absorbed systemically which is therefore available to produce a biological effect. Future 38 
studies should be conducted with larger samples, different age groups and using different F doses.  39 
 40 
  41 
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1 Introduction 42 
While the effectiveness of topical exposure to fluoride (F) in the prevention of dental caries has been 43 
well demonstrated, excessive exposure to systemic F can have some health side effects including 44 
dental and skeletal fluorosis (ten Cate and Buzalaf, 2019). Undesirable health effects of F can be 45 
related not only to the body’s total F intake but, more importantly, to the extent of F retention in the 46 
body. Genetic and environmental factors such as stage of skeletal development, acid-base balance and 47 
exercise have been suggested to influence metabolism and body retention of F (Buzalaf and Whitford, 48 
2011; Buzalaf, 2018). Understanding F metabolism and its physiological characterisation is therefore 49 
very important if we are to avoid or minimise side effects of systemic F exposure. 50 
The pharmacokinetics of F is mainly controlled by pH and storage in bone, because the coefficient of 51 
permeability of lipid bilayer membranes to hydrogen fluoride (HF) is a million times higher than to F 52 
ion (Buzalaf and Whitford, 2011). Therefore, factors affecting systemic pH (in cells, tissues and 53 
fluids) could play an important role in the body’s absorption, distribution, excretion and retention of 54 
F. After absorption, F concentrations of plasma rise promptly due to the rapid absorption of F from 55 
the stomach and reach their peak within 20-60 min. Plasma F concentration normally returns to pre-56 
ingestion levels during the next few hours depending on the F dose. Plasma F concentrations are not 57 
homeostatically controlled and therefore fluctuate according to the F dose, body deposition and 58 
excretion. Under normal conditions, almost 60% of a healthy adult’s and 45% of a healthy child’s 59 
daily absorbed F is excreted in urine and most (about 99%) of the body-retained F is associated with 60 
calcified tissues (Buzalaf and Whitford, 2011). 61 
F has been reported as one of a few known agents that can stimulate osteoblast proliferation (Palmer 62 
and Wolfe, 2005). However, different doses of F display a biphasic effect on osteoclast cell viability, 63 
differentiation, formation and function:  a low F dose stimulates them, whereas a high dose inhibits 64 
them (Yu et al., 2018). Furthermore, a decline in expression of osteocytes but a rise in expression of 65 
osteoblasts has been linked to exercise (Schwab and Scalapino, 2011), in particular weight-bearing 66 
exercise (Willems et al., 2017). Therefore, the pharmacokinetics of F may be influenced by alterations 67 
in physiological responses to acute and chronic exercise. Changes in body F retention could be 68 
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important in terms of the effect of F on tooth and bone development and the timing of F ingestion 69 
when fluorides are used in dental caries prevention. 70 
The literature is sparse and contradictory in terms of the effect of exercise on pharmacokinetics of F in 71 
humans. The only human experimental study, comparing F concentration in plasma and urine between 72 
exercised and non-exercised groups, reported higher plasma F concentrations with moderate and 73 
vigorous intensity exercise as well as a reduction in urinary F excretion with moderate exercise 74 
compared with a non-exercised control in young adults (Zohoori et al., 2015). Conversely, two animal 75 
studies have reported a significant reduction in plasma F concentration in rats exposed to a one-hour 76 
treadmill running exercise (Whitford, 1996; Lombarte et al., 2013). More recently, an animal study 77 
(Amaral et al., 2018) reported no effect of high intensity training exercise on plasma F in fluorosis-78 
susceptible mice.  79 
The aim of this present study was to investigate the F pharmacokinetics following no exercise and 80 
three exercise intensity conditions (light, moderate and vigorous) in healthy adults. The objectives 81 
were to compare urinary F excretion (UFE) and plasma F concentration among no, light, moderate 82 
and vigorous exercise intensities.  83 
 84 
2 Methods: 85 
2.1 Participants 86 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all 87 
procedures involving human participants were approved by the Research Governance and Ethics 88 
Committee, School of Health and Social Care, Teesside University (Protocol number 066/15). Prior to 89 
the experiment, all participants provided written informed consent.  90 
The target sample size for this exploratory study was eight participants, based on the only human 91 
study by Zohoori et al (n=9) (Zohoori et al., 2015) as well as the animal studies by Whitford (n=8) 92 
(Whitford et al., 1988), Lombarte et al (n=10) (Lombarte et al., 2013) and Amaral et al (n=8) (Amaral 93 
et al., 2018). 94 
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The study participants were healthy adult volunteers, from both genders; aged between 18 and 35 95 
years; weighing over 50 kg; with no history of acid-base disturbance and not receiving a therapeutic 96 
diet. Participants had to be considered at least moderately active according to the International 97 
Physical Activity Questionnaire (i.e.  5 or more days of moderate-intensity activity of at least 30 min 98 
per day) (Craig et al., 2003) and “ready” to engage in the prescribed exercise according to the 99 
Physical Activity Readiness Questionnaire (American College of Sports Medicine, 2007). All 100 
participants were residing in a non-fluoridated area, with a water F concentration of <0.3 ppm.  101 
2.2 Experimental Design 102 
This experiment was designed as a four-treatment repeated measures cross-over study, comparing 103 
observations within individuals.  104 
Pre-experimental Procedures 105 
Participants were invited to attend a pre-experimental session, when height and weight was measured 106 
using a stadiometer (Leicester Height Measure, Child Growth Foundation, London, United Kingdom) 107 
and a calibrated scale (Seca 220, Seca Weighing and Measuring Systems, Germany). Each individual 108 
participant underwent a VO2 max test, performed following a standard cycle ergometer protocol (Evans 109 
and White, 2009) to determine the exercise intensities (light, moderate and vigorous) for the 110 
experimental sessions. Following a 5-minute warm up at 25 Watts, the test started at 25 Watts with 111 
the intensity being increased by 25 Watts every 2 minutes until exhaustion. Cycle ergometer power 112 
output (PowerTap Cycleops400, USA) and participant’s Rate of Perceived Exertion (RPE) using the 113 
CR-10 RPE scale (Noble et al., 1983) were recorded every minute. Heart rate was monitored 114 
throughout the exercise sessions with a heart rate monitor (Polar RS400, Polar Electro Oy, Finland) 115 
and recorded at every minute during exercise. The three exercise intensities (light, moderate and 116 
vigorous) were determined by using the v-slope method (Beaver et al., 1986) and defined for each 117 
participant as: (i) light intensity: one load below Ventilatory Threshold (VT) 1; (ii) moderate 118 
intensity: the load at VT and; (iii) vigorous intensity: one load above VT. 119 
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In order to minimise F exposure from all other sources during the study, participants were placed on a 120 
F-free regime one week before, as well as during, the whole experimental period. They were provided 121 
with a F-free toothpaste to use and instructed to avoid drinking tea, beer and tap-water (if leaving their 122 
stated residential area) and eating seafood during the washout and experimental periods (i.e. for a total 123 
of five consecutive weeks). Participants were asked to refrain from performing exercise, other than 124 
habitual walking, for 48h prior to and during experimental sessions. 125 
Experimental sessions  126 
After the one-week washout period, each participant underwent four randomly allocated experimental 127 
sessions; one no-exercise (control) session and three exercise sessions at different intensities (light, 128 
moderate and vigorous) with approximately a week’s gap between sessions (Figure 1).  129 
The study was conducted in an exercise laboratory at the same time of day for all experimental 130 
sessions to control for circadian rhythms.  131 
Participants attended the laboratory at around 9:00 am on each experiment day, having fasted 132 
overnight. A venous cannula was inserted into the antecubital fossa of each participant’s arm, by an 133 
experienced nurse, for intravenous blood samples collection (as explained in the next section). A 134 
baseline venous blood sample (5ml) was collected from each participant before they were provided 135 
with a low-F breakfast (<10µgF) which comprised a cereal bar, a banana and fruit juice. In order to 136 
control the influence of F from diet during the experimental sessions, the same standardised low F 137 
breakfast was consumed by all participants at approximately the same time in each of their four 138 
sessions. 139 
After breakfast, all participants (in both control and exercise sessions) were given a 1mgF tablet 140 
(Endekay Fluotabs 2.2mg NaF, Manx Pharma Ltd, Warwick, UK) to ingest. Participants then either 141 
rested (control session) or undertook the exercise (exercise sessions) at approximately 9:30am. 142 
Participants from the exercise group were fitted with a heart rate monitor belt (Polar RS400, Polar 143 
Electro Oy, Finland). Participants warmed up for 5 minutes at a self-selected speed before initiating 144 
the designated exercise intensity on the cycle ergometer for 20 minutes.  145 
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2.3 Sample collection 146 
Urine samples 147 
Pooled urine samples were collected by spontaneous voiding over a 24h cycle during four time 148 
periods: 1) A nocturnal sample collected from midnight before the experimental (control or exercise) 149 
session up until about 09.00am (Baseline, pre-F tablet/pre-exercise); 2) A ‘09.00am to 12.00pm’ 150 
sample during the experimental session (0-3h post-F tablet ingestion); 3) A ‘12.00pm to 17.00pm’ 151 
sample during the experimental session (3-8h post-F tablet ingestion) and; 4)  A ‘17.00pm through to 152 
just before bed-time’ sample (~23.00pm) on the experimental day (8-14h post-F tablet ingestion). 153 
Blood plasma:  154 
A 5ml venous blood sample was collected after overnight fasting, prior to taking breakfast (Baseline, 155 
T0). An additional four blood samples (5ml/sample) were then collected at 30, 45, 60 and 90 minutes 156 
after ingestion of the F-tablet, providing samples T1 to T4.  157 
2.4 Analytical Procedure 158 
F concentration (g/ml) of urine samples was measured directly after adding total ionic strength 159 
adjustment buffer III (Orion Research) to standards and samples, using a F-ion-selective electrode (F-160 
ISE, Model Orion 9609BNWP, Thermo Scientific, USA) coupled to a potentiometer (Model 720A+). 161 
F concentrations in plasma (ng/ml) and breakfast items (µg/g) were measured, in triplicate, by a 162 
hexamethyldisiloxane (HMDS)-facilitated diffusion method (Taves, 1968) which has been previously 163 
reported in detail (Martínez-Mier et al., 2011). In summary, 1 ml H2SO4 saturated with HMDS was 164 
added to 1 ml of sample (and standards) in a petri-dish and left at room temperature to diffuse 165 
overnight. An alkaline solution (50 µl of NaOH (0.05N), placed as 5 drops on the inside of the dish 166 
lid), was used to trap the released F. After a minimum of 16h diffusion, the NaOH drops were 167 
combined as a single drop and 20 µl acetic acid (0.20N) added. The F-ISE electrode was then placed 168 
in contact with the combined solution and the mV reading recorded. A calibration curve was used to 169 
calculate F concentration of the sample. 170 
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The reliability of the methods used was specifically confirmed by re-analysis of a minimum 10% of 171 
samples. All sample analysis and re-analysis was conducted in triplicate. 172 
1.2.5 Data handling and analysis 173 
Urine: 174 
Urinary F excretion (UFE) in each individual time-controlled urine sample was calculated by 175 
multiplying the F concentration (µg/ml) of the urine sample by its corresponding volume (ml).  176 
Baseline-adjusted UFE was calculated by subtracting the baseline UFE from the UFE of each sample. 177 
The sums of the amount of F excreted in urine for the periods during and after each experimental 178 
session for each participant were used to calculate the total post-F tablet UFE (Periods 2-4 inclusive: 179 
representing a 14h period).  180 
The UFE rate (g/h) for each given time period was calculated by dividing UFE for each time period 181 
by the duration of the corresponding collection period (h).  182 
Overall relative UFE (%) was calculated by dividing the baseline-adjusted UFE (µg) for a given time 183 
period by the ingested F dose (i.e. 1 mg=1000 µg) multiplied by 100.  184 
Plasma:  185 
Baseline-adjusted plasma F concentration (ngF/ml) was calculated by subtracting the baseline plasma 186 
F concentration from the F concentration in each plasma sample.  187 
Maximum F concentration (Cmax) was calculated using the mean maximum baseline-adjusted plasma 188 
F concentration following F dose. Lag time to maximum F concentration (Tmax) was estimated using 189 
graphs plotting plasma F concentration against time. Area under the curve (AUC) (ng/min/ml) was 190 










iiii ttcc , where:  192 
(t) is the number of minutes after F dose - the first time point is time 0 and (Ci) is the value of C at 193 




2.6 Statistical Analysis 196 
Descriptive data are presented and statistically significant differences among groups were initially 197 
detected using repeated measures ANOVA and further investigated using a post-hoc test (Tukey). 198 
Statistical significance was set at α < 0.05 and all analysis performed using SPSS version 22. 199 
 200 
3 Results: 201 
All those invited participated and eight participants (4 males and 4 females) took part in the study. 202 
The mean (SD) age, height, weight and BMI for females were: 23.7 (7.2) years, 165.5 (3.5) cm, 64.2 203 
(2.5) kg and 23.5 (1.6) kg/m2; and for males were: 25.0 (6.0) years, 176.2 (6.0) cm, 74.2 (9.9) kg and 204 
23.7 (2.1) kg/m2, respectively.   205 
3.1 Accuracy of the analytical method 206 
The accuracy of the analytical method was confirmed by comparing the analysis and re-analysis 207 
measurements. The results showed no statistically significant differences between the two sets of 208 
measurements. The mean (SD) difference for urine samples was 0.009 (0.002) mgF/l (n=16) and for 209 
plasma samples was 0.004 (0.001) ngF/ml (n=20).  210 
3.2 Comparison of control (no exercise) and the three different exercise intensities 211 
Mean (SD) exercise loads for light, moderate and vigorous exercise intensities were 62.5 (37.5), 87.5 212 
(37.5) and 112.5 (37.5) Watts for females and 68.7 (37.0), 106.2 (37.0) and 137.5 (37.5) Watts for 213 
males, respectively. Mean (SD) maximum heart rates (HR) were 176.0 (12.6) and 160.7 (25.7) bpm 214 
and mean RPEs (Rate of Perceived Exertion) at the end of the VO2 max test were 4.7 (0.8) and 7.7 (1.3) 215 
in females and males, respectively.  216 
Mean (SD) plasma F concentrations, during the control and exercise sessions, according to the 217 
different time periods are presented in Table 1 and the pharmacokinetic variables in Table 2.   218 
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Overall, a total of 32 experimental sessions were undertaken by the eight participants. Mean (SD) 219 
baseline fasting plasma F concentration was 31.80 (26.2) ng/ml. Mean baseline-adjusted plasma F 220 
concentrations across the 90 minutes post-F ingestion for all experimental sessions are shown in 221 
Figure 2.   222 
All experimental sessions followed a similar trend in plasma F concentration, peaking between 30 to 223 
60 minutes post-F ingestion with a Tmax ranging from 43 min for light exercise to 50 and 51 min for 224 
control and vigorous exercise, respectively. The highest Cmax was found for moderate exercise 225 
(226.2 ngF/ml) followed by light (105.6 ngF/ml), vigorous exercise (94.2 ngF/ml) and control (27.0 226 
ngF/ml).  AUC(0-90min) ranged from 15058 ngF/min/ml for moderate exercise to 1474 ngF/min/ml for 227 
control.  228 
Repeated measures analysis of variation (ANOVA) showed no statistically significant difference in 229 
Tmax among all sessions, whereas Cmax for moderate exercise was statistically significantly higher 230 
compared to no (p < 0.001), light (p = 0.016) and vigorous (p = 0.008) exercise. AUC(0-90min) was also 231 
statistically significant higher at moderate exercise intensity compared to no (p < 0.001), light (p = 232 
0.004) and vigorous (p = 0.001) exercise.   233 
The mean (SD) UFE at baseline was 109.2 (100.7) µgF for the total of 32 experimental sessions 234 
undertaken overall by the eight participants. Mean (SD) UFEs for the different time periods during the 235 
control and exercise sessions are presented in Table 3.  236 
No statistically significant differences in UFE were found between the no exercise and three different 237 
exercise intensities for any individual time period, nor for total post-F tablet period (i.e. 0-14h post-F 238 
tablet ingestion). 239 
Mean baseline-adjusted UFE rates across the 4 time-controlled periods of urine collection are shown 240 
in Figure 3.  241 
Light, moderate and vigorous intensity exercise resulted in lower mean baseline-adjusted UFE rates 242 
over the 0-3h post-F tablet period (light 41.1, moderate 25.6 and vigorous 35.3µgF/h,) in comparison 243 
with no exercise (62.6µgF/h); however, the differences were not statistically significant. Furthermore, 244 
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there were no statistically significant differences in baseline-adjusted UFE rates among different 245 
exercise intensities (including no exercise) for any individual time period. 246 
Mean overall relative UFE (i.e. proportion of ingested F dose excreted in urine) for each time period 247 
was 21% for 0-3h post-F tablet, 20% for 3-8h post-F tablet and 16% for 8-14h post-F tablet, with an 248 
overall relative UFE of 59% for 0-14h post-F tablet.  249 
 250 
4 Discussion: 251 
This study provides the first data on the effects of exercise on F pharmacokinetics in healthy adults. 252 
The results suggest that moderate exercise may result in higher F absorption and consequently higher 253 
body F retention. These observations could be particularly important in communities with fluoridation 254 
programmes such as school-based milk fluoridation where children consume fluoridated milk just 255 
before mid-morning playtime (e.g. in UK school milk fluoridation programmes). 256 
The mean Tmax (50 min) and AUC(0-90min) (1474 ngF/min/ml) reported in our study for the control 257 
session (no exercise, received 1mgF tablet) were within the corresponding ranges of 43.1-56.6 min 258 
and 752-1562 ngF/min/ml, respectively,  reported for 21-35 year old English adults given a F dose of 259 
0.5 mg (500 ml of fluoridated water containing almost 1mgF/L) (Maguire et al., 2005). However, the 260 
mean Cmax (27.0 ng/ml) for the no exercise (control) session in our study was higher than the 261 
corresponding range of 9.2-19.0 ng/ml reported for English adults (Maguire et al., 2005). Since F 262 
dose is an important factor influencing F pharmacokinetics, the observed higher pharmacokinetic 263 
parameters in our study, compared to the study by Maguire et al (2005) could be explained by the 264 
larger amounts of F ingested by participants in our study. 265 
Our study found a non-statistically significant trend for an overall lower UFE with greater exercise 266 
intensity. However, the overall mean plasma F concentrations at different time points, as well as 267 
Cmax and AUC(0-90min) were higher for the exercise sessions compared to the no exercise (control) 268 
session (Tables 1 and 2; Figure 1). These findings imply that exercise could affect the 269 
pharmacokinetics of F, i.e. increasing F absorption but decreasing F excretion. However, the 270 
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mechanisms by which exercise could alter F metabolism remain unclear. The increase in cardiac 271 
output and consequently muscle and skeletal blood flow following exercise may lead to an increase in 272 
the rate of F absorption and body distribution to muscles and bones. Additionally, exercise could 273 
affect renal clearance of F from kidneys in two ways: (a) increase the activity of sympathetic nervous 274 
system, resulting in vasoconstriction within the kidney which would then reduce renal blood flow and 275 
glomerular filtration rate (GFR); and (b) increase production of lactic acid by muscle which would 276 
increase the renal reabsorption of F (Whitford, 1996; Buzalaf and Whitford, 2011). These changes 277 
would further lessen the renal excretion of F but tend to increase levels of F in plasma. 278 
Our study found no statistically significant difference in Tmax among different intensities of exercise 279 
including no exercise (control). However, our study showed that the mean values for Cmax and 280 
AUC(0-90min) were statistically significantly higher for moderate exercise compared with light and 281 
vigorous exercise as well when compared with no exercise (control). A study with nine adults 282 
(Zohoori et al., 2015) also reported higher plasma F concentrations, although not statistically 283 
significant, for moderate intensity exercise compared with control, light and vigorous exercise.  284 
Gastric emptying has been shown to increase with increasing exercise intensities up to 65% VO2 max 285 
(moderate intensity), but it decreases above an intensity of 75% VO2 max (vigorous intensity) 286 
(Neufer, 1989). Cardiac output following an increased work rate increases in an almost linear manner 287 
to meet the increasing oxygen demand but only up to the point where maximal capacity is reached 288 
(Manley 1996). This may explain the higher mean plasma F concentration, Cmax and AUC(0-90min) for 289 
the moderate compared to vigorous exercise as participants may have reached their maximum cardiac 290 
output when exercising at vigorous intensity. Future studies are therefore needed to include 291 
interventions where participants undertake an exercise routine at different intensities (light, moderate 292 
and vigorous), for a prolonged period of time.  293 
Urine is the major excretion route for systemically absorbed bioavailable F, with the majority of an 294 
ingested F dose appearing in the urine within the first three hours (Zipkin and Leone, 1957). Our 295 
study showed that, on average, 59% of daily intake of F was excreted in urine, over a 24h period,  296 
which is in agreement with the suggested corresponding figure of 60% for healthy adults (Buzalaf and 297 
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Whitford, 2011). Our study also found that, on average, 21% of ingested F dose was excreted in urine 298 
during the first three hours following F ingestion, corresponding to the value of 20% reported for 299 
healthy adults (Zipkin and Leone, 1957).  300 
Our study showed a lower, although not statistically significant, UFE rate over the first 3h period for 301 
moderate exercise compared with light and vigorous exercise as well as when compared with no 302 
exercise (Table 3).  However, the UFE rate tended to be higher over the 3-14h period for moderate 303 
exercise compared with other exercise intensities including no exercise.  These findings indicate that 304 
moderate exercise may lead to a delay in urinary F excretion in adults. The lower UFE rate over the 305 
first 3h period could be explained by the increased production of lactic acid, leading to a more acidic 306 
urine and consequently resulting in a higher proportion of ingested F being reabsorbed (i.e. lower 307 
urinary F excretion). In addition, it is known that a steady-state relationship exists between plasma F 308 
levels and the hydration shell of the bone crystallites (Rao et al., 1995). Thus, another possibility is 309 
that moderate exercise increases the absorption of F, thus augmenting plasma F levels, which in turn 310 
would increase F uptake in the hydration shell of the bone crystallites. As plasma F levels start to 311 
decrease after the peak is reached, then F present in the hydration shell of the bone crystallites is 312 
released back into plasma and excreted in urine over time.  313 
In order to reduce dental caries in children, public health initiatives such as school fluoridated milk 314 
programmes have been rolled out across schools in some counties including the UK (Banoczy et al., 315 
2009). However, previous studies have indicated that  current UK milk fluoridation programmes do 316 
not provide adequate protection for the prevention of dental caries (Ketley and Lennon, 2000). It has 317 
been reported that increasing the school milk F dose from 0.5mg to 0.9mg per 189ml, in the UK, may 318 
still be too low to achieve the World Health Organisation recommended UFE concomitant with 319 
optimal F exposure for children aged < 6y (World Health Organization, 2014). In the UK, fluoridated 320 
milk, is often provided to schoolchildren during their mid- morning break before undergoing physical 321 
activity. In addition, UK children’s physical activity levels during break have been reported to be 322 
predominantly moderate (Powell et al., 2016). According to our findings, the low UFE observed 323 
(Maguire et al., 2013) during monitoring of fluoridated milk programmes may therefore be related to 324 
14 
 
the effect of moderate physical activity, that children undertake during their breaks, on F absorption 325 
and excretion. F concentrations in blood and urine have been shown not to be influenced by sex 326 
(Torra et al., 1998; Del Carmen et al., 2016)  However, due to the possible different physiological 327 
responses following exercise in children compared to adults, as well as females compared to males, 328 
further work is required to determine the effects of exercise on F metabolism in young children and 329 
different sexes. These findings can help inform the evidence base for stakeholders and decision 330 
makers in dental public health as well as health professionals who may wish to review F dose and 331 
time of administration in different fluoridation programmes. 332 
The main limitations of our study are: (i) the sample size; although the number of participants in this 333 
study are comparable with other similar studies in humans (Zohoori et al., 2015) and animals (Whitford 334 
et al., 1988; Lombarte et al., 2013); (ii) the F dose; which was based on the optimal F concentration of 335 
drinking water of 1mg/l, and; (iii) the inclusion of only one age group (young adults). Since the peak 336 
plasma and bone F concentrations are directly related to both the age of the individual and F intakes, 337 
any extrapolation of the study findings to other age groups should be made with caution. 338 
Our study also indicated large variation in pharmacokinetic variables between individuals. A study by 339 
Ekstrand [Ekstrand, 1978] with a family of five, aged 10 to 38 years old, who ate together and received 340 
a water supply with 9.6 ppm F, showed a large variation in plasma F concentration between family 341 
members and a much greater within-individual variation during the day (e.g.  40-110 ng/ml for an adult 342 
family member). Some of the relatively wide variation in pharmacokinetic variables between 343 
participants might be explained by between-individual differences in physiological variables such as 344 
volume and pH of gastric secretions, gastro-intestinal motility, plasma volume, and urinary pH. 345 
In conclusion, this human experimental study adds to the understanding of the effects of exercise on F 346 
metabolism. The findings suggest that moderate exercise may increase the fraction of ingested F 347 
absorbed systemically and therefore available to produce a biological effect. In addition, moderate 348 
exercise may have a tendency to delay the excretion of F in urine.   349 
  350 
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Table 1. Mean (SD) plasma fluoride (F) concentrations (ngF/ml), during experimental sessions; no 439 
exercise (control), light, moderate and vigorous exercise. 440 
 441 
 442 







Light Moderate Vigorous 
30 minutes (T1) 20.4 (14.7) 150.9 (54.9) 241.3 (130.1) 93.8 (36.7) 
45 minutes (T2) 29.6 (16.6) 147.9 (77.5) 263.1 (113.6) 136.9 (59.8) 
60 minutes (T3) 33.6 (26.9) 134.6 (104.7) 238.7 (74.1) 127.5 (24.9) 
90 minutes (T4) 16.6 (12.5) 110.0 (98.7) 205.2 (83.3) 111.4 (42.9) 
20 
 
Table 2. Mean (SD) pharmacokinetic parameters for plasma following ingestion of fluoride (F) tablet 444 
(1.0 mg F) by exercise intensity.  445 
 446 
 447 
a) Lag time to maximum F concentration 448 
b) Maximum F concentration 449 
c) Area under the curve 450 
  451 
Pharmacokinetic parameters 




Light Moderate Vigorous 
Tmax (min)a 50.3 (11.0) 42.9 (13.5) 45.9 (10.5) 51.3 (10.9) 
Cmax (ngF/ml)b 27.0 (24.3) 105.6 (41.7) 226.2 (115.6) 94.2 (58.1) 
AUC (0-90min) (ngF.min.ml-1)c 1474 (939) 6920 (3506) 15058 (6596) 5542 (2264) 
21 
 
Table 3. Mean (SD) urinary fluoride excretion (UFE; µgF) for different time-controlled periods 452 
during experimental sessions for no exercise (control), light, moderate and vigorous exercise. 453 
 454 




Light Moderate Vigorous 
UFE0-3h (9:00 – 12:00) 302.7 (354.4) 222.3 (64.0) 119.4 (132.4) 213.5 (100.0) 
UFE3-8h (12:00 – 17:00) 214.0 (167.8) 207.4 (116.4) 242.9 (100.3) 130.8 (74.1) 
UFE8-14h (17:00 – 23:00) 130.3 (122.2) 196.0 (206.7) 207.8 (134.7) 124.5 (52.5) 















Figure 1. Experimental procedure and sample collection 467 
 468 







Figure 2.  Baseline-adjusted plasma F concentration (ng/ml) over the 0 - 90 minute post F ingestion 474 
period. 475 
 476 















































Figure 3. Mean baseline-adjusted UFE rate (µgF/h) across the 4 time-controlled periods of collection 481 
according to exercise intensity;  no exercise (control (blue line)), light (green line), moderate (brown 482 
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